Oragenics (OGEN) Other Non-Current Assets (2015 - 2024)
Oragenics' (OGEN) quarterly Other Non-Current Assets came in at $1.1 million in Q3 2024, up 12583.14% YoY from N/an in Q4 2023, and little changed on a QoQ basis from $1.1 million in Q2 2024.
Oragenics (OGEN) Other Non-Current Assets (2015 - 2024) Analysis & Trends
Oragenics (OGEN) has 6 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q3 2024.
- Quarterly Other Non-Current Assets rose 12583.14% year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (up 12583.14% YoY) and the FY2023 annual result came in at $1.1 million, up 5979.99% from the prior year.
- Other Non-Current Assets was little changed at $1.1 million in Q3 2024, from $1.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q4 2023 to a low of $8600.0 in Q3 2023.
- A 4-year average of $374765.0 and a median of $17940.0 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 52.06% — and 2024, when it surged 12583.14%.
- Tracing OGEN's Other Non-Current Assets over 4 years: stood at $17940.0 in 2021, then changed by 0.0% to $17940.0 in 2022, then jumped by 5979.99% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
- The last three Other Non-Current Assets figures came in at $1.1 million (Q3 2024), $1.1 million (Q2 2024), and $1.1 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 62.96 Mn |
| 10 | Oragenics | 2.32 Mn | 2.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 8,600.00 |
| Jun 30, 2023 | 17,940.00 |
| Mar 31, 2023 | 17,940.00 |
| Dec 31, 2022 | 17,940.00 |
| Sep 30, 2022 | 17,940.00 |
| Jun 30, 2022 | 17,940.00 |
| Mar 31, 2022 | 17,940.00 |
| Dec 31, 2021 | 17,940.00 |
| Jun 30, 2016 | 13,575.00 |
| Dec 31, 2015 | 345,074.00 |